170 related articles for article (PubMed ID: 31742861)
1. TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.
Zhu M; Yang L; Shi X; Gong Z; Yu R; Zhang D; Zhang Y; Ma W
J Cell Mol Med; 2020 Jan; 24(1):984-995. PubMed ID: 31742861
[TBL] [Abstract][Full Text] [Related]
2. A novel biphenyl urea derivate inhibits the invasion of breast cancer through the modulation of CXCR4.
Zhan Y; Zhang H; Li J; Zhang Y; Zhang J; He L
J Cell Mol Med; 2015 Jul; 19(7):1614-23. PubMed ID: 25753200
[TBL] [Abstract][Full Text] [Related]
3. A novel biphenyl urea compound, TPD7, stimulates apoptosis through modulating Fas signaling and Bcl-2 family proteins in cervical cancer.
Zhan Y; Zhang H; Dai B; Zhang Y; Zhang J; He L
Oncol Rep; 2018 Aug; 40(2):1064-1072. PubMed ID: 29901176
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Effect of TPD7 and Berberine against Leukemia Jurkat Cell Growth through Regulating Ephrin-B2 Signaling.
Ma W; Zhu M; Yang L; Yang T; Zhang Y
Phytother Res; 2017 Sep; 31(9):1392-1399. PubMed ID: 28703366
[TBL] [Abstract][Full Text] [Related]
5. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Wozniak MB; Villuendas R; Bischoff JR; Aparicio CB; Martínez Leal JF; de La Cueva P; Rodriguez ME; Herreros B; Martin-Perez D; Longo MI; Herrera M; Piris MA; Ortiz-Romero PL
Haematologica; 2010 Apr; 95(4):613-21. PubMed ID: 20133897
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
7. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
8. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP.
Sumarni U; Reidel U; Eberle J
Cells; 2021 Apr; 10(5):. PubMed ID: 33922439
[TBL] [Abstract][Full Text] [Related]
9. TPD7 inhibits the non-small cell lung cancer HCC827 cell growth by regulating EGFR signalling pathway.
Zhang X; Zhang H; Qi G; Gu X; Zhao Y; Zhang J
J Chemother; 2022 Apr; 34(2):110-116. PubMed ID: 34210250
[TBL] [Abstract][Full Text] [Related]
10. ND-16: A Novel Compound for Inhibiting the Growth of Cutaneous T Cell Lymphoma by Targeting JAK2.
Zhu M; Liu Y; Lei P; Shi X; Tang W; Huang X; Pan X; Wang C; Ma W
Curr Cancer Drug Targets; 2022; 22(4):328-339. PubMed ID: 35220934
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
12. Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis.
Abdulrahman N; Leo R; Boumenar HA; Ahmad F; Mateo JM; Jochebeth A; Al-Sowaidi NK; Sher G; Ansari AW; Alam M; Uddin S; Ahmad A; Steinhoff M; Buddenkotte J
Leuk Lymphoma; 2023 Dec; 64(14):2236-2248. PubMed ID: 37708450
[TBL] [Abstract][Full Text] [Related]
13. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.
Li H; Wang C; Ma P; Zhang M; Yang H; Yuan S; Wei J; Tao L; Qian K; Xu M; Li L
J Dermatol Sci; 2020 Mar; 97(3):208-215. PubMed ID: 32165081
[TBL] [Abstract][Full Text] [Related]
14. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
[TBL] [Abstract][Full Text] [Related]
18. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells.
Qin JZ; Zhang CL; Kamarashev J; Dummer R; Burg G; Döbbeling U
Blood; 2001 Nov; 98(9):2778-83. PubMed ID: 11675351
[TBL] [Abstract][Full Text] [Related]
20. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
Zhang Q; Nowak I; Vonderheid EC; Rook AH; Kadin ME; Nowell PC; Shaw LM; Wasik MA
Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9148-53. PubMed ID: 8799169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
